Spyre Therapeutics stock soared to a four-year high Monday on positive 12-week test results for its ulcerative colitis ...

April 13 () - Spyre Therapeutics said on Monday its experimental drug demonstrated a significant reduction ‌in disease ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

An experimental monoclonal antibody treatment appears to ease the digestive disorder ulcerative colitis in patients who've failed other medications, a new trial shows. The treatment, tulisokibart, ...

Spyre Therapeutics hit the key target in a trial of its candidate treatment for moderate to severely active ulcerative colitis. The clinical-stage biotechnology company said Monday it achieved ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

Biologic therapy within a year of diagnosis could decrease risk for disease progression among patients with ulcerative ...

The FDA approved Omvoh, a medication that treats ulcerative colitis developed by drugmaker Eli Lilly. The injection is the first treatment for ulcerative colitis that targets p19, a specific protein ...

Add Yahoo as a preferred source to see more of our stories on Google. “Debilitating digestive issues dominated my life because I couldn’t go longer than a half hour without going to the bathroom,” ...

What Is Infusion for Ulcerative Colitis? If your doctor has recommended infusion therapy, this is probably because standard treatment hasn’t helped relieve symptoms caused by moderate-to-severe ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

By Siddhi Mahatole April 13 (Reuters) - Spyre Therapeutics said on Monday its experimental drug showed a significant reduction in disease activity when tested in patients with ulcerative colitis in a ...